A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses
A New Class of Synthetic Peptide Inhibitors Blocks Attachment and Entry of Human Pathogenic Viruses
复制标题
DOI：
10.1093/infdis/jis273
复制
发表时间：
2012-06-01
影响因子：
6.4
通讯作者：
Protzer, Ulrike
中科院分区：
文献类型：
--
作者：
Krepstakies, Marcel;Lucifora, Julie;Protzer, Ulrike
许多包膜病毒，包括疱疹病毒、乙型肝炎病毒（HBV）、丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV），是最重要的人类病原体之一，经常导致涉及>= 2种病毒的合并感染。然而，对多种病毒有效的治疗方法很少。在这里，我们提出了一类新的合成抗脂多糖肽（salp），它与细胞表面的硫酸肝素片段结合，并抑制多种包膜病毒的感染。我们证明salp抑制人类免疫缺陷病毒1型（HIV-1）、单纯疱疹病毒（HSV） 1和2、HBV和HCV进入其各自的宿主细胞。尽管salp具有很高的抗病毒效率，但耐受性良好，并且没有观察到毒性或可测量的抑制剂诱导的不良反应。由于这些广谱抗病毒肽针对宿主细胞而不是病毒成分，因此它们也可能对抑制对抗病毒药物具有抗性的病毒有用。
Many enveloped viruses, including herpes viruses, hepatitis B virus (HBV), and hepatitis C virus (HCV), and human immunodeficiency virus (HIV), are among the most important human pathogens and are often responsible for coinfections involving >= 2 types of viruses. However, therapies that are effective against multiple virus classes are rare. Here we present a new class of synthetic anti-lipopolysaccharide peptides (SALPs) that bind to heparan sulfate moieties on the cell surface and inhibit infection with a variety of enveloped viruses. We demonstrate that SALPs inhibit entry of human immunodeficiency virus type 1 (HIV-1), herpes simplex virus (HSV) 1 and 2, HBV, and HCV to their respective host cells. Despite their high antiviral efficiency, SALPs were well tolerated, and neither toxicity nor measurable inhibitor-induced adverse effects were observed. Since these broad-spectrum antiviral peptides target a host cell rather than a viral component, they may also be useful for suppression of viruses that are resistant to antiviral drugs.